TP53 and endometrial cancer: Conversely, in endometrial cancer cells expressing an oncogenic gain-of-function p53 mutation, synthetic lethality was induced by combining paclitaxel with BIBF1120 and a histone deacetylase inhibitor, which served to destabilize mutant p53.